iProgen Biotech and the University of British Columbia (UBC) have jointly out-licensed their novel modular Degrader Antibody Conjugate (DAC) technology to 3C Therapeutics Inc., (www.3Ctherapeutics.com) headquartered in Vancouver, British Columbia. This licensing agreement marks the successful culmination of a collaborative research effort between David Perrin’s laboratory in the Department of Chemistry at UBC and iProgen Biotech. The development of this innovative technology was supported by funding from the Natural Sciences and Engineering Research Council of Canada (NSERC).
